Making sense of the ageing methylome

Nature Reviews Genetics, Год журнала: 2022, Номер 23(10), С. 585 - 605

Опубликована: Май 2, 2022

Язык: Английский

---

Intracellular and Intercellular Aspects of Macrophage Immunometabolism in Atherosclerosis

Circulation Research, Год журнала: 2020, Номер 126(9), С. 1209 - 1227

Опубликована: Апрель 23, 2020

Macrophage immunometabolism, the changes in intracellular metabolic pathways that alter function of these highly plastic cells, has been subject intense interest past few years, part because macrophage immunometabolism plays important roles atherosclerosis and other inflammatory diseases. In this review article, Compendium on Atherosclerosis , we introduce concepts (1) immunometabolism—the canonical intrinsic cell activation leading to metabolism, which turn cellular function; (2) intercellular immunometabolism—conditions intermediates metabolism are transferred from one another, thereby altering recipient cell. The recent discovery metabolite cargo dead dying cells ingested through efferocytosis by macrophages can downstream efferocyte is markedly changing way think about immunometabolism. Metabolic transitions contribute their functions all stages atherosclerosis, lesion initiation formation advanced lesions characterized necrotic cores, regression following aggressive lipid lowering. This article discusses advances our understanding different aspects atherosclerosis. With increasing new exciting potential targets for intervention emerging.

Язык: Английский

---

Precision medicine in non-small cell lung cancer: Current applications and future directions

Seminars in Cancer Biology, Год журнала: 2020, Номер 84, С. 184 - 198

Опубликована: Июль 27, 2020

Язык: Английский

---

Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management

American Journal of Hematology, Год журнала: 2020, Номер 95(11), С. 1399 - 1420

Опубликована: Авг. 3, 2020

Abstract Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk transformation to acute myelogenous leukemia (AML). Myelodysplastic occur more frequently in older males individuals with prior exposure cytotoxic therapy. Diagnosis MDS is based on morphological evidence dysplasia upon visual examination bone marrow aspirate biopsy. Information obtained from additional studies such as karyotype, flow cytometry molecular genetics usually complementary may help refine diagnosis. Risk‐stratification Prognosis patients can be calculated using number scoring systems. In general, all these systems include analysis cytopenias, percentage blasts the cytogenetic characteristics. most commonly accepted system Revised International Prognostic Scoring System (IPSS‐R). Somatic mutations define prognosis Risk‐adapted therapy Therapy selected risk, transfusion needs, percent blasts, mutational profiles, comorbidities, potential for allogeneic stem cell transplantation (alloSCT) hypomethylating agents (HMA). Goals different lower‐risk than higher‐risk those HMA failure. MDS, goal decrease needs higher disease or AML, well improve survival. disease, prolong 2020, we witnessed an explosion new investigational approaches. Current available therapies growth factor support, lenalidomide, HMAs, intensive chemotherapy alloSCT. Novel therapeutics approved 2020 luspatercept oral ASTX727. At present time, there no interventions progressive refractory particularly after HMA‐based Options participation clinical trial, cytarabine‐based

Язык: Английский

---

Association of Clonal Hematopoiesis With Incident Heart Failure

Journal of the American College of Cardiology, Год журнала: 2021, Номер 78(1), С. 42 - 52

Опубликована: Июнь 28, 2021

Язык: Английский

---